- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ascelia Pharma AB (ACELP)
Ascelia Pharma AB stock price live, this page displays ST ACELP stock exchange data. View the ACELP premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Ascelia Pharma AB real time stock price chart below.
What Is the Ascelia Pharma AB Stock Price Today?
The Ascelia Pharma AB stock price today is 0.631.
What Is the Stock Symbol for Ascelia Pharma AB?
The stock symbol for Ascelia Pharma AB is "ACELP."
What Stock Exchange Does Ascelia Pharma AB Trade On?
Ascelia Pharma AB is listed and trades on the Stockholm stock exchange.
Is Ascelia Pharma AB a Good Stock to Buy?
Determining whether Ascelia Pharma AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ACELP quote. (ISIN: SE0010573113)
What Is the Ascelia Pharma AB Stock Price Today?
The Ascelia Pharma AB stock price today is 0.631.
What Is the Stock Symbol for Ascelia Pharma AB?
The stock symbol for Ascelia Pharma AB is "ACELP."
What Stock Exchange Does Ascelia Pharma AB Trade On?
Ascelia Pharma AB is listed and trades on the Stockholm stock exchange.
Is Ascelia Pharma AB a Good Stock to Buy?
Determining whether Ascelia Pharma AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ACELP quote. (ISIN: SE0010573113)
0.631
+0.008(+1.28%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.603
0.632
52 wk Range
0.455
5.050
ACELP is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.6030.632
52 wk Range
0.4555.050
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ACELP Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Ascelia Pharma AB Earnings Call Summary for Q2/2026
- Ascelia Pharma narrowed Q2 loss to SEK 12M through cost cuts after FDA issued Complete Response Letter for lead drug Orviglance in July.
- Cash position stood at SEK 38M at quarter-end with runway into Q2 2025, assuming minimal resubmission requirements from regulators.
- Sept. 9 FDA Type A meeting is critical catalyst; regulatory issue centers on image interpretation, not trial conduct or safety data.
- Shares fell 1.69% to $0.58, near 52-week low, as investors await clarity on approval timeline and potential additional funding needs.
- CEO Corfitzen maintains Orviglance's $800M market opportunity remains intact; second asset Oncoral could become strategic option if needed.
Last Updated: 08/21/2026, 04:36 PM
Read Full TranscriptEarnings
Latest Release
Aug 20, 2026
EPS / Forecast
-0.09 / --
Revenue / Forecast
-- / --
Compare ACELP to Peers and Sector
Metrics to compare | ACELP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipACELPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.4x | −2.8x | −0.4x | |
PEG Ratio | −0.03 | −0.04 | 0.00 | |
Price/Book | 0.9x | 5.5x | 2.6x | |
Price / LTM Sales | - | 24.1x | 3.1x | |
Upside (Analyst Target) | 284.3% | 87.2% | 48.2% | |
Fair Value Upside | Unlock | −9.5% | 6.5% | Unlock |
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. The company was incorporated in 1999 and is headquartered in Malmö, Sweden.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Ascelia Pharma (ACELP) Stock Price Today?
The Ascelia Pharma stock price today is 0.631 SEK.
What Stock Exchange Does Ascelia Pharma Trade On?
Ascelia Pharma is listed and trades on the Stockholm Stock Exchange.
What Is the Stock Symbol for Ascelia Pharma?
The stock symbol for Ascelia Pharma is "ACELP."
What Is the Ascelia Pharma Market Cap?
As of today, Ascelia Pharma market cap is 84.260M SEK.
What Is Ascelia Pharma's Earnings Per Share (TTM)?
The Ascelia Pharma EPS (TTM) is -0.477.
When Is the Next Ascelia Pharma Earnings Date?
Ascelia Pharma will release its next earnings report on Nov 05, 2026.
From a Technical Analysis Perspective, Is ACELP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Ascelia Pharma Stock Split?
Ascelia Pharma has split 0 times.
How Many Employees Does Ascelia Pharma Have?
Ascelia Pharma has 10 employees.
What is the current trading status of Ascelia Pharma (ACELP)?
As of Aug 29, 2026, Ascelia Pharma (ACELP) is trading at a price of 0.631 SEK, with a previous close of 0.623 SEK. The stock has fluctuated within a day range of 0.603 SEK to 0.632 SEK, while its 52-week range spans from 0.455 SEK to 5.050 SEK.
What Is Ascelia Pharma (ACELP) Price Target According to Analysts?
The average 12-month price target for Ascelia Pharma is 2.388 SEK, with a high estimate of 3.7 SEK and a low estimate of 1 SEK. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +278.37% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.